The DAPA-CKD trial demonstrated the benefit of dapagliflozin in CKD patients regardless of the presence or absence of type 2 diabetes. What was the primary composite outcome significantly reduced in this trial?

• A Cardiovascular death and hospitalisation for heart failure
• B All-cause mortality in CKD stages 3–4
• C Reduction in proteinuria by >50% from baseline
• D Sustained ≥50% eGFR decline, ESKD, renal death, or cardiovascular death ✓

Explanation

The DAPA-CKD trial (NEJM 2020) showed that dapagliflozin significantly reduced the primary composite of sustained ≥50% eGFR decline, end-stage kidney disease, cardiovascular death, or kidney disease-related death by 39% compared to placebo in patients with CKD (eGFR 25–75 mL/min, ACR ≥200 mg/g), independent of diabetes status. This led to approval of SGLT2 inhibitors for CKD with proteinuria beyond T2DM.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.